Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 3, 2014, Pages 343-351

  Elsberger, Beatrix ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Breast cancer; Src kinase; Src kinase inhibitors; Translational research

Indexed keywords

BREAST CANCER; SRC KINASE; SRC KINASE INHIBITORS; TRANSLATIONAL RESEARCH;

BREAST NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84893758436     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.12.009     Document Type: Review

References (42)

1. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602:114-130.
2. Yeatman T.J. A renaissance for SRC. Nat Rev Cancer 2004, 4:470-480.
3. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
4. Frame M.C., Fincham V.J., Carragher N.O., Wyke J.A. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002, 3:233-245.
5. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005, 331:1-14.
6. Ly Q.P., Yeatman T.J. Clinical relevance of targeted interference with Src-mediated signal transduction events. Recent Results Cancer Res 2007, 172:169-188.
7. Stover D.R., Furet P., Lydon N.B. Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem 1996, 271:12481-12487.
8. Mayer B.J. SH3 domains: complexity in moderation. J Cell Sci 2001, 114:1253-1263.
9. Elsberger B., Tan B.A., Mitchell T.J., et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients. Am J Pathol 2009, 175:1389-1397.
10. Bjorge J.D., Jakymiw A., Fujita D.J. Selected glimpses into the activation and function of Src kinase. Oncogene 2000, 19:5620-5635.
11. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
12. Zhang X.H., Wang Q., Gerald W., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
13. Elsberger B., Fullerton R., Zino S., et al. Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br J Cancer 2010, 103:899-909.
14. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996, 180:383-388.
15. Kanomata N., Kurebayashi J., Kozuka Y., Sonoo H., Moriya T. Clinicopathological significance of Y416Src and Y527Src expression in breast cancer. J Clin Pathol 2011, 64:578-586.
16. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the Src and Abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326.
17. Campbell E.J., McDuff E., Tatarov O., et al. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 2008, 99:1769-1774.
18. Morgan L., Gee J., Pumford S., et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 2009, 8:1550-1580.
19. Anbalagan M., Moroz K., Ali A., Carrier L., Glodowski S., Rowan B.G. Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer. PLoS One 2012, 7:e33017.
20. Poulard C., Treilleux I., Lavergne E., et al. Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med 2012, 4:1200-1213.
21. Planas-Silva M.D. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006, 341:73-81.
22. Elsberger B., Paravasthu D.M., Tovey S.M., Edwards J. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. J Cancer Res Clin Oncol 2012, 138:327-332.
23. Zhang L., Teng Y., Zhang Y., et al. c-Src expression is predictive of poor prognosis in breast cancer patients with bone metastasis, but not in patients with visceral metastasis. AMPIS 2012, 120:549-557.
24. Herold C.I., Chadaram V., Peterson B.L., et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 2011, 17:6061-6070.
25. Finn R.S., Bengala C., Ibrahim N., et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011, 17:6905-6913.
26. Fedele P., Calvani N., Marino A., et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going. Crit Rev Oncol Hematol 2012, 84:243-251.
27. Ito Y., Kawakatsu H., Takeda T., et al. Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat 2002, 76:261-267.
28. Elsberger B., Tan B.A., Mallon E.A., Brunton V.G., Edwards J. Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. Br J Cancer 2010, 103:1831-1834.
29. Kawakatsu H., Sakai T., Takagaki Y., et al. A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase. J Biol Chem 1996, 271:5680-5685.
30. Johnson D., Agochiya M., Samejima K., Earnshaw W., Frame M., Wyke J. Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ 2000, 7(8):685-696.
31. Giannoni E., Fiaschi T., Ramponi G., Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009, 28(20):2074-2086.
32. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999, 71(3/4):435-478.
33. Weis S., Cui J., Barnes L., Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004, 167(2):223-229.
34. Criscuoli M.L., Nguyen M., Eliceiri B.P. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005, 105(4):1508-1514.
35. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375(6532):577-581.
36. Fincham V.J., Frame M.C. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J 1998, 17(1):81-92.
37. Avizienyte E., Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005, 17(October (5)):542-547.
38. Mayer E., Baurain J., Sparano J., et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011, 17:6897-6904.
39. Somlo G., Atzori F., Strauss L.C., et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res 2013, 19:1884-1893.
40. Fornier M.N., Morris P.G., Abbruzzi A., et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011, 22:2575-2581.
41. http://clinicaltrials.gov/.
42. Campone M., Bondarenko I., Brincat S., et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012, 23:610-617.